Earkart Q3 FY26 Earnings Analysis
Published 7 Aug 2026 | Healthcare Equipment & Supplies | Market Cap: ₹192 Cr
Price
₹140
Market Cap
₹192 Cr
P/E Ratio
39.0
Revenue Rank
Margin Rank
Earnings Summary
- Earkart aims to reach approximately ₹300 crore turnover in 5 years (by 2030). - Earkart aims to become a ₹300 crore company within 5 years (by 2030).
📊 Revenue & Sales Performance
Rank 2- Earkart aims to reach approximately ₹300 crore turnover in 5 years (by 2030). - Targeting 500 to 550 clinic installations by FY 2027, with installation cost per device around ₹2.7 lakh per clinic. - Expecting a compound annual growth rate (CAGR) of about 25% this year and aiming to sustain similar growth next year. - Private sector revenue share expected to grow to about 70% within 5 years, with government orders range-bound around 20-30%. - Revenue from clinics expected to rise significantly, e.g., from 110 clinics generating roughly ₹10-11 crore at full capacity. - Focus on expanding geographical presence across India, moving from North to West, South, and eventually East. - Anticipate operational cost enhancements with increased hiring and infrastructure to support expansion; margins expected between 20-30% EBITDA. - Private market margins up to 40-45% gross margin projected with increasing private sector focus.
📈 Profitability & Margins
Rank 3- Earkart aims to become a ₹300 crore company within 5 years (by 2030). - Target to scale up to 500-550 clinics by FY27, with ~₹70,000 installation cost per clinic, funded by IPO proceeds. - EBITDA margins expected between 20-30%, aiming for 23% EBITDA margin this year as expansion costs stabilize. - Gross margins around 40-45% on private sales; government segment margins at 29-32%. - Private sector revenue share expected to increase to ~70% by 2028, with government orders range-bound at 20-30%. - Long-term growth driven by expansion beyond North India to West and South, then East regions. - Operating efficiency expected to rise to 70-80% in 12-19 months, improving margins further. - EPS growth implied via scaling revenue and maintaining healthy margins, with profitability improving as expansions mature.
🏗️ Capital Expenditure Plans
Yes- The company has planned installation of around 500 to 550 clinics by the end of FY 2027. - The installation cost per device is approximately ₹2.7 lakh per clinic. - Recent IPO proceeds include unutilized funds sufficient to cover the capex for clinic installations. - By the time 350 installations are achieved, the business model is expected to become self-sustaining. - Expansion involves hiring more employees and setting up new infrastructure to support growth. - Investments are also being made in improving the OMNI Audiometer for better efficiency and availability. - Strategic expansion planned geographically from North India towards West, South, and eventually East India. - Efforts include partnerships with financial institutions (e.g., zero pay NBFC) for interest-free EMI offerings to customers. - Focus on reducing customer acquisition costs by positioning products within ENT practices. Overall, a clear strategy of measured capital expenditure aligned with clinic expansion and technological improvements is in place.
💰 Fundraising & Capital Structure
No information- There is no explicit mention of any current or planned new fundraising through debt or equity during the call. - Mr. Rohit Misra confirms that sufficient funds are already available following the recent IPO to support the planned expansion, including the installation of devices in clinics. - The company has made provisions to ensure the model becomes self-sustaining by the time of 350 installations. - No mention of additional debt or equity fundraising plans was discussed for future financing. - The focus is on efficient cash use and organic growth, leveraging the existing IPO proceeds for capex and expansion.
📋 Order Book & Pipeline
Yes- Earkart has already secured government orders worth approximately ₹9 crores in the current fiscal year (Page 8, 7th excerpt). - Four government tenders, usually opening before September, were deferred but two have already opened, with 2-3 more expected to open in the second half of the fiscal year (Page 8). - The second half of the year is expected to see a significant scale-up in order inflows due to these tender openings (Page 8). - Private sector orders have grown by over 25% compared to last year, supporting overall revenue despite deferred government orders (Page 8). - The company aims for a 25% compound annual growth rate (CAGR) this year, driven by both government and private orders (Page 8). - No explicit total value of the full order book or pending orders beyond these notes was mentioned in the transcript.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Earkart Q3 FY26 results?
- Earkart aims to reach approximately ₹300 crore turnover in 5 years (by 2030). - Earkart aims to become a ₹300 crore company within 5 years (by 2030).
What is Earkart share price analysis?
Earkart currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 39.0 with a market cap of ₹192. Investors should review the full earnings analysis for detailed insights.
Is Earkart planning capital expenditure?
- The company has planned installation of around 500 to 550 clinics by the end of FY 2027.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
